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Outcome of Patients With Small Vessel
Vasculitis After Renal Transplantation: National
Database Analysis
Amr El-Husseini, MD,1,2 Sherif Saleh, MSc,1 Omer Hamad, BSc,1 Xiaonan Mei, MSc,3 Ana Lia Castellanos, MD,1
Daniel L. Davenport, PhD,4 Roberto Gedaly, MD,2 and B. Peter Sawaya, MD1
Background.Small vessel vasculitis commonly affects the kidney and can progress to end-stage renal disease. The goal of this
study is to compare outcomes of patients who received a renal transplant as a result of small vessel vasculitis (group A) with those
who received kidney transplants because of other causes (group B).Methods.This is a retrospective analysis of United Network
for Organ Sharing registry data for adult primary kidney transplants from January 2000 to December 2014. Group A patients
(N = 2196)were comparedwith a groupB (N= 6588); groupswere casematched for age, race, sex, donor type, and year of trans-
plant in a 1:3 ratio. Results. Renal and patient survivals were better in the group A (P < 0.001). New-onset diabetes after trans-
plant developed in 8.3% of the group A and 11.3% of group B (P < 0.001). Seventeen (0.8%) patients in group A developed
recurrent disease. Of these, 7 patients had graft failure, 3 of which were due to disease recurrence. Group A patients had signif-
icantly higher risk of developing posttransplant solid organ malignancies (11.3% vs 9.3%, P = 0.006) and lymphoproliferative dis-
order (1.3% vs 0.8%, P = 0.026). Independent predictors of graft failure and patient mortality were recipients' morbid obesity,
diabetes, age, and dialysis duration (hazard ratio of 1.7, 1.4, 1.1/10 years, and 1.1/year for graft failure, and 1.7, 1.7, 1.6/10 years
and 1.1/year for patient mortality, respectively). Conclusions. Renal transplantation in patients with small vessel vasculitis has
favorable long-term graft and patient outcomes with a low disease recurrence rate. However, they may have a higher risk of
developing posttransplant malignancies.
(Transplantation Direct 2018;4: e350; doi: 10.1097/TXD.0000000000000769. Published online 20 February, 2018.)
Vasculitides, an immune reactive inflammation in vesselwalls, often presents as serious and sometimes fatal dis-
eases that require prompt diagnosis and therapy.1 In 2012,
the International Chapel Hill Consensus Conference revised
the nomenclature of vasculitides.2 Noninfectious vasculitides
are classified based on size: large-, medium-, and small-sized
vessel vasculitis. Small vessel vasculitis (SVV) includes a vari-
ety of serious diseases, such as Henoch-Schoenlein purpura
(HSP), anti-glomerular basement membrane (GBM) disease,
and antineutrophil cytoplasmic antibody (ANCA) associated
vasculitis, which includes granulomatosis with polyangiitis
(GPA), eosinophilic GPA (Churg-Strauss syndrome), micro-
scopic polyangiitis (MPA), and renal limited ANCA vasculi-
tis.2-4 SVV affects the kidney and can progress to end-stage
renal disease (ESRD) in approximately 20% to 40% of
cases.5-8 Of these ESRD patients, around 30% have received
a renal transplant in the last 2 decades.7
Patientswith SVVand anti-GBMhave often undergone cy-
totoxic treatments for their disease and generally have longer
exposure to immunosuppressive medications, which may in-
crease their risk of cancer and infection. Subsequently, this
can negatively impact graft and patient survival. However,
using Organ Procurement and Transplantation Network/
United Network of Organ Sharing (UNOS) data, Shen et al5
reported that patient and graft outcomes in kidney transplant
recipients with GPAwere superior to those who received re-
nal transplants due to other causes. Similarly, Kanaan et al6
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reported favorable graft and patient outcomes in patients
with HSP after kidney transplantation. These studies, along
with others, have shown that the risk of disease recurrence
in SVV patients, although relatively low, may still occur
and contribute to graft loss.5,6,9 There have been limited data
on postrenal transplant nonvasculitic comorbidities, such as
diabetes, malignancies, cytomegalovirus (CMV), or other in-
fections, which are known to result from immunosuppres-
sion in these patients.9
To date, there is no large study that looks at posttransplant
outcomes in patients with SVV and anti-GBM disease other
than survival. Moreover, most previous studies focused only
on ANCA-associated vasculitis. The goal of this study is to
analyze 1-, 5- and 10-year graft and patient survivals using
UNOS database in patients with SVVand anti-GBM disease
after renal transplantation and comparing their outcomes
with case-matched control patients. Furthermore, this study
assesses other outcomes, such as disease recurrence, new-onset
diabetes after transplantation (NODAT), posttransplant
CMV infection, and malignancies.
MATERIALS AND METHODS
The current study is a retrospective analysis of 15 years of
UNOS registry data for primary kidney-alone transplanta-
tion from January 1, 2000, toDecember 31, 2014. Outcomes
of adult patients with SVV and anti-GBM disease are com-
pared with a control group of renal transplant patients. Case
controls were matched in a 1:3 ratio for recipients' age (exact
age by years), sex, race, year of transplantation (categorized
to 3 groups), donors' type (deceased or live). The matching
was undertaken to eliminate the confounding effect of sig-
nificant recipient and donor variables on outcomes. Three
matched controls were selected for each study patient
yielding a total sample size of 8784 with 2196 patients in
the cohort and 6588 case controls. We excluded patients
younger than 18 years at the time of kidney transplant
and those with simultaneous or more than 1 organ trans-
plantation. Data analysis included the cause of ESRD,
presence of pretransplant diabetes, whether the patient re-
ceived preemptive kidney transplantation, dialysis dura-
tion before transplantation, body mass index (BMI), HLA
mismatch, cold ischemia time, delayed graft function, acute
cellular rejection (ACR) within 6 and 12 months of renal
transplantation, induction agents used, and maintenance im-
munosuppressive regimen.
The outcomes studied included renal allograft and patient
survival, vasculitis recurrence, NODAT, the development of
posttransplant malignancies, and CMV seroconversion. Uni-
variate comparisons of continuous variables were performed
using t test orMann-WhitneyU test, depending on the distri-
bution. Variables were analyzed across categories using anal-
ysis of variance orχ2 tests as appropriate. A P value less than
0.05 was considered significant for all tests. A Kaplan-Meier
analysis was performed to compare renal allograft and pa-
tient survival differences among the groups using log rank
tests. Using Cox regression modeling, graft failure and pa-
tient death were adjusted to the following covariates: BMI,
diabetes, age, dialysis duration, PRA percentage, and HLA
mismatch. The proportional hazard’s assumption was tested
through insertion of a time and effect interactive term in the
Cox models. Sensitivity to competing risk was assessed by
analyzing the impact of competing death risk on the allograft
survival. We compared graft and patient survival based on
etiology of ESRD and diabetic status of the patients as well
as according to the type of vasculitis (anti-GBM disease,
GPA, MPA, and HSP). Statistical analysis was performed
using SPSS version 24 (IBM Inc., Armonk, NY, USA) except
for the competing risk modeling which was performed using
SAS version 9 (SAS Inc., Cary, NC).
RESULTS
We identified 2197 patients with SVV and anti-GBM dis-
ease from the UNOS data set (group A), and successfully
matched 2196 of them with 6588 patients in the data set
(group B). The mean age of patients was 48.8 ± 15.9 years.
The majority were white (80.0%) and male (55.1%). Most of
the organs came from young, white, deceased donors (Table 1).
In groupA, 1167hadGPA, 675had anti-GBMdisease, 174had
HSP vasculitis, 173 hadMPA, and 7 patients hadChurg-Strauss
syndrome. The main reason for kidney failure in group B was
glomerular diseases (25.2%), diabetes (21.8%), hypertension
(17.4%), and polycystic kidney disease (11.8%).
The mean ± SD BMI for the group Awas 26.55 ± 5.29 and
27.44 ± 5.54 in group B (P < 0.001). Before renal transplan-
tation, 6.3% of group A patients had diabetes mellitus com-
pared with 27.9% in group B (P < 0.001). More patients in
groupA had dialysis before renal transplantation with longer
mean dialysis duration (P < 0.001 and 0.014, respectively).
Group A patients had higher PRA% but better HLA cross-
matching (P=0.008andP<0.001, respectively).Thymoglobulin
was the most widely used induction agent in both groups. The
majority of patients in both groups receivedmaintenance ste-
roids, tacrolimus, andmycophenolatemofetil. There were no
statistical significant differences between groups regarding
induction and maintenance immunosuppressive regimens. The
demographic and transplant-specific characteristics of each
group are detailed in Table 1.
The median graft survival time was 13.0 years (95% confi-
dence interval [CI], 11.9-14.2) in group A and 10.6 years
(95% CI, 10.5-10.7) in group B patients (P < 0.001). The me-
dian patient survival time was 14.3 years (95% CI, 13.4-15.2)
in group A and 12.3 years (95% CI, 12.2-12.4) in group B pa-
tients (P < 0.001). The 1-, 5-, and 10-year graft survival was
95.5%, 83.1%, and 59.6% in group A, respectively, and
93.9%, 77.0%, and 54.3% in group B patients, respectively
(Figure 1). The 1-, 5-, and 10-year patient survival was 98.3%,
90.2%, and 68.9% in group A, respectively, and 97.1%,
85.0%, and 62.8% in group B patients, respectively (Figure 2).
In group A, 9.7% of patients were lost to follow-up at a median
time of 3.9 years. For the group B patients, 10.0% of patients
were lost to follow-up at a median time of 3.5 years.
Compared with diabetic patients, those who did not have
diabetes had better graft and patient survivals in both groups
(Figures 3 and 4, P < 0.001 in both). The estimated graft and
patient survivals were better in patients with polycystic kid-
ney disease andwere worst for patients who had diabetic ne-
phropathy as a reason for ESRD (Figures 5 and 6, P <0.001
in both). There were no statistical significant differences in
graft survival between the 4 vasculitis subgroups (Figure 7,
P = 0.375). Kidney transplant recipients with GPA had the
lowest, whereas HSP patients had the highest patient sur-
vival compared with the other 2 subgroups with MPO and
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anti-GBM disease (Figure 8, P < 0.001). There was no signif-
icant difference in CMV seroconversion in both groups
(P = 0.187 and 0.841, for IgG and IgM, respectively).
NODAT developed in 8.3% of patients among group A
and 11.3% in group B (P < 0.001).
Disease Recurrence
Seventeen patients in the group A developed disease recur-
rence (0.8%). The mean time to disease recurrence was
24.4 ± 15.0 months. Seven of these patients had graft failure,
3 due to disease recurrence, with the remaining 4 due to other
reasons. Details of the timing and impact of recurrence on re-
nal transplant and patient survival are described in Table 2.
Posttransplant Malignancies
More patients in group A developed solid-organ malig-
nancies and posttransplant lymphoproliferative disorder
(PTLD) (P = 0.006 and 0.026, respectively). There was no
TABLE 1.
Demographic and transplant-specific characteristics of matched patients
Variables Group A (n = 2196) Group B (n = 6588) P
Recipient age at transplant (mean ± SD), y 48.78 ± 15.86 48.78 ± 15.86 1.000
Donor age at transplant (mean ± SD), y 39.28 ± 14.96 39.58/± 14.93 0.479
Recipient race—white (%) 1754 (79.9%) 5262 (79.9%) 1.000
Donor race—white (%) 1756 (80.0%) 5184 (78.7%) 0.204
Recipient sex—male (%) 1211 (55.1%) 3633 (55.1%) 1.000
Donor sex—male (%) 1093 (49.8%) 3325 (50.5%) 0.571
Donor Type—deceased (%) 1214 (55.3%) 3642 (55.3%) 1.000
Donor cause of death—trauma (%) 469 (21.4%) 1442 (21.9%) 0.601
Transplant years 1.000
2000-2004 712 (32.4%) 2136 (32.4%)
2005-2009 766 (34.9%) 2298 (34.9%)
2010-2014 718 (32.7%) 2154 (32.7%)
Recipient BMI, kg/m2 <0.001
< 18.5 77 (3.5%) 197 (3.0%)
18.5-29.9 1605 (73.1%) 4362 (66.2%)
30.0-39.9 484 (22.0%) 1919 (29.1%)
≥ 40 30 (1.4%) 110 (1.7%)
Pretransplant diabetes, n (%) 138 (6.3%) 1835 (27.9%) <0.001
Pretransplant dialysis, n (%) 1913 (87.1%) 5050 (76.7%) <0.001
Dialysis duration (mean ± SD), y 2.44 ± 2.36 2.28 ± 2.44 0.014
PRA % (mean ± SD) 13.97 ± 28.12 11.71 ± 25.72 0.008
HLA mismatch, n (%)
0 270 (12.3%) 636 (9.7%) <0.001
1-2 360 (16.4%) 959 (14.6%)
3-4 860 (39.2%) 2675 (40.6%)
5-6 696 (31.7%) 2294 (34.8%)
Cold ischemia time (mean ± SD), h 11.49 ± 10.66 12.19 ± 10.73 0.924
Delayed graft function, n (%) 264 (12.0%) 861 (13.1%) 0.203
ACR within 6 mo, n (%) 156 (7.1%) 443 (6.7%) 0.714
ACR within 12 mo, n (%) 167 (7.6%) 523 (7.9%) 0.134
Induction agent, n (%) 0.762
Alemtuzumab 220 (10.0%) 691 (10.5%)
Thymoglobulin 809 (36.8%) 2404 (36.5%)
Basiliximab 470 (21.4%) 1311 (19.9 %)
Maintenance immunosuppressive regimen, n (%)
Steroids 1490 (71.5%) 4408 (71.7%) 0.876
Calcineurin inhibitors 0.094
Cyclosporine-based regimen 249 (11.3%) 869 (13.2%)
Tacrolimus-based regimen 1788 (81.4%) 5229 (79.4%)
Antimetabolites 0.628
Azathioprine 25 (1.1%) 51 (0.8%)
Mycophenolate mofetil 1549 (70.5%) 4593 (69.7%)
Mycophenolic acid 351 (16.0%) 1139 (17.3%)
mTOR inhibitors 0.503
Sirolimus 124 (5.6%) 412 (6.3%)
Everolimus 14 (0.6%) 35 (0.5%)
Shaded variables were exactly matched between cohorts.
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significant difference between both groups in the occurrence
of skin cancers or recurrence of primary malignancies after
transplantation. There was no available information about
Epstein-Barr virus (EBV) status at the time of cancer diagno-
sis. However, at the time of transplantation, there was no sig-
nificant difference in the EBV serology status between the
groups (Table 3).
Adjusted Graft and Patient Survival Using Cox
Regression Modeling
Multivariable Cox regression analysis showed that inde-
pendent predictors of graft failure and patient mortality were
recipients' morbid obesity, diabetes, age, and dialysis dura-
tion (hazard ratio [HR] of 1.7, 1.4, 1.1/10 years, and 1.1/year
for graft failure, and 1.7, 1.7, 1.6/10 years and 1.1/year for
patient mortality, respectively). After adjustment for these
factors, patients with vasculitis or anti-GBM disease main-
tained favorable graft and patient survival (HR, 0.8 and 0.9
for graft failure and patient death, respectively) (Table 4
and 5). Application of a competing risks (graft failure and
death) model had no impact on the vasculitis HRs. Analyses
of interactions with a time-dependent covariate were not sig-
nificant, confirming the proportional hazards assumptions
were met.
Causes of Kidney Allograft Loss
Chronic allograft nephropathy was the most common
cause of graft loss among both groups (65% in group A
and 64% in group B). Acute rejection was the second most
common cause of graft loss (23% and 29%, in group A
and group B, respectively). Deathwith a functioning graft oc-
curred in 11% of patients in group A and 15% in group B.
None of these results were statistically significant between
the 2 groups.
Cause of Death
The most common cause of death in group A was malig-
nancies (21%), followed by infections (16%), then cardiovas-
cular complications (14%). Themost common cause of death
in group B was cardiovascular events (21%), followed by in-
fections (15%), then malignancies (12%). Unfortunately, the
cause of death was frequently missing in the UNOS data set
(24% for group A and 28% for group B).
DISCUSSION
Because of the low incidence of SVV and anti-GBM dis-
eases among renal transplant recipients, there is a paucity
of large studies evaluating these patients' outcomes. Most
of these studies focused only on ANCA-associated vasculitis
especially GPA. In this study, using the most recent UNOS
data, we compared outcomes of renal transplant patients
with anti-GBM disease, ANCA-associated vasculitis (GPA
and MPA), and HSP with those who had ESRD secondary
to other nonvasculitis causes. Overall, patients with SVVor
anti-GBM diseases had relatively better outcome in terms of
graft and patient survivals. The SVV and anti-GBM groups
were matched to the comparison group by age, race, sex, do-
nor type, and year of transplantation to mitigate the effect of
differences in baseline characteristics between both groups.
The SVVand anti-GBM cohorts had some favorable charac-
teristics, including fewer HLA mismatches and particularly
less diabetes. However, more patients in this group had dial-
ysis before renal transplantation with a longer dialysis dura-
tion and overall higher PRA%. Some single-center and
limited national studies have reported that the graft and pa-
tient survivals for renal transplant recipients with SVV are
comparable to other renal transplants.5,6,10-13 However, sev-
eral other studies have also reported high recurrence rates of
vasculitis after renal transplantation.14-20 When we com-
pared survivals after excluding diabetic patients in both the
SVV and non-SVV groups, the SVV group still had better
graft survival. Yet, when we compared only patients with di-
abetes in both groups, superior survivals were no longer ap-
preciative in the SVV group. In this study, diabetic renal
transplant patients had worse outcomes whether they have
SVV, anti-GBM disease, or not. Other studies had reported
a similar observation which was mostly attributed to in-
creased cardiovascular risks in diabetic patients.5,21 Lim
and colleagues22 investigated in a population cohort study
the long-term outcome of kidney transplantation in patients
with type 2 diabetes. They found that kidney transplant
FIGURE1. Graft survival among the2groupsusingKaplan-Meiercurves.
FIGURE2. Patient survival amongthe2groupsusingKaplan-Meiercurves.
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recipients with type 2 diabetes had significantly poorer patient
survival, with 5-year mortality rates exceeding those of nondia-
betic patients by over twofold, especially in those younger than
40 years. Furthermore, compared with the general population,
there was no evidence of improvement in mortality over time
among diabetic patients after kidney transplantation.
There is paucity of information on the nonvasculitic co-
morbidities, such as infections and malignancies that affect
SVV patients after renal transplantation. Also, the frequency
of relapses and the influence of disease type on these patients
are lacking. Hruskova et al23 suggested that such information
will require collaboration among the transplant and vasculitis
centers and the establishment of a large registry. In this study,
we tried to explore some of these issues at a national level.
Recurrence
Posttransplant recurrence of vasculitis and anti-GBM dis-
ease is a major concern for this group of patients. The
reported recurrence rate in the literature has been quite vari-
able.6,24-29 Interestingly, in this study, we found a very low re-
current vasculitis rate that was rarely the cause of graft loss in
this cohort. We do not have data on disease control or anti-
body titers at the time of transplantation; however, most of
these patients were on dialysis for more than a year, and they
were likely in remission at the time of transplantation. Six
(0.9%) of 675 patients had recurrence in the anti-GBM sub-
group. A study in the Australia and New Zealand registry
found that 2.7% of patients developed biopsy-proven recur-
rent anti-GBM disease, which led to graft failure in less than
0.5% of patients.30 They also reported that the graft and pa-
tient survivals were better than other patients transplanted
for ESRD from other causes. In an older European study,
the frequency of recurrent disease was much higher at
14%,31 which may reflect differences in immunosuppressive
use during an earlier era and shorter dialysis duration before
renal transplantation in the European study. For example,
FIGURE 3. Graft survival in patients with and without vasculitis and diabetes using Kaplan-Meier curves.
FIGURE 4. Patient survival in patients with and without vasculitis and diabetes using Kaplan-Meier curves.
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Briganti et al32 studied the risk of renal allograft loss from re-
current glomerulonephritis in Australia. They did not ob-
serve any recurrence in patients with anti-GBM disease up
to 10 years after transplantation. Of note, the practice in
Australia is to defer transplantation for 12 months after the
completion of treatment in cases of anti-GBM disease.
In this study, the recurrence rates of other vasculitis sub-
groups are as follows: HSP, 5.7%; GPA, 0.1%; and MPA,
0%. The recurrence rate of our patients with HSPwas higher
compared with other types of vasculitis. In concordance with
our results, several studies have reported a high recurrence
rate (15% to 53%) after renal transplantation in HSP pa-
tients.13,33,34 Gera et al,25 in a single-center study, found the
recurrence rate of ANCA-associated vasculitis after renal
transplantation to be 8.6%. They were unable to identify
clear risk factors for recurrence, and their patients had satis-
factory response to treatment with no deleterious effect on re-
nal transplant function. Other studies have reported quite
variable relapse rates for ANCA-associated vasculitis. For ex-
ample, Marco et al35 reported a relapse rate of 0.01 per
patient per year, whereas Nachman et al19 in an older study
reported rates as high as 17%. In concordance with our
study, Westman et al28 reported that the relapse rate may
be higher in GPA compared with MPA patients.
Influence of Disease Type onGraft and Patient Survival
in Group A Patients (Subgroup Analysis)
We did not find a significant difference in graft survival in
group A patients based on the type of the disease. However,
patients with GPA had a lower patient survival. Tang et al36
studied the outcomes of 228 MPA and 221 GPA patients in
Australia and New Zealand in a multicenter study. They
found that graft survival in GPA patients was comparable
to non-SVV patients but superior to MPA patients, and
MPA patients had worse renal and patient survivals. There
were no significant differences in baseline characteristics be-
tweenMPA and GPA patients except thatMPA patients were
older. Themean age of our patients with SVVwas 48.8 years,
whereas the mean age in Tang et al's study was older than
60 years. Suppiah et al37 studied the cardiovascular events
FIGURE 5. Graft survival stratified to the reason for ESRD.
FIGURE 6. Patient survival stratified to the reason for ESRD.
FIGURE 7. Graft survival in group A according to the disease type.
FIGURE 8. Patient survival in group A according to the disease type.
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in patients with GPA andMPA. They found that those with a
PR3-ANCA showed a reduced cardiovascular risk compared
with those with a MPO-ANCA. Cardiovascular risk factors
were not assessed in our study.
NODAT
The incidence and impact of NODATon patient and renal
survival has not been clearly reported in the literature in pa-
tients with vasculitis. In this study, fewer patients in the
SVV and anti-GBM disease group developed NODAT after
transplantation compared with the nonvasculitis group.
This might be explained by the fact that SVV and anti-
GBM patients had a significantly lower BMI and less meta-
bolic syndrome compared with the comparison group. The
reported incidence of NODAT is variable and must be
interpreted in the context of definition used, time from trans-
plant, study population, and immunosuppressive agents
used. Studies reported rates ranging from 7% to 46%.38,39
NODAT adversely affects long-term allograft survival. In 1
study, graft survival at 12 years was 22% less in those with
NODAT; this was associated with a 3.7 relative risk of graft
loss.40 The consequences of NODAT in vasculitis patients
require further studies.
Infections
CMV seroconversion was not significantly different be-
tween the 2 study groups. In previous studies, the frequency
of infections posttransplantation, in general, was not a major
concern in patients with ANCA-associated vasculitis23 and
HSP patients.33 The details of infections are not reported in
the UNOS database; therefore, we were unable to study in
depth the rate and outcomes of infections in our cohort.
Malignancies
In this study, more patients in the group A developed solid
organ malignancies and PTLD. In agreement with this find-
ing, several studies have reported an increased cancer risk
in patients with SVVand anti-GBMdiseases. Hoffman et al41
reported an overall increased cancer risk of 2.4with a 33-fold
increased risk for urinary bladder cancer and an 11-fold in-
creased risk for lymphoma in patients with GPA. Similar
findings of an increased risk of 1.6 to 3.8 for all sites of cancer
were later reported in the literature.42-45 In a recent analysis
of patients with SVVand anti-GBM disease, Deegens et al46
noted a significant increase in malignancies (mainly skin can-
cer) after renal transplantation compared with a matched
control group. In contrast, a study from Germany showed
no increased risk of cancer at all sites among patients with
ANCA-associated vasculitis.47 Also in a single-center study,
Marco et al35 did not find differences in the incidence of can-
cer in patients with ANCA-associated vasculitis after renal
transplantation. In a previous UNOS analysis, the reported
incidence of cancer in patients with GPA was not different
(2.9%) compared with other ESRD transplant recipients
TABLE 2.
Recurrent vasculitis after renal transplantation (17 patients)
Patient Disease type Time of recurrence, d Graft failure Graft failure cause Death
1 Anti-GBM 168 No Not applicable No
2 HSP 347 No Not applicable No
3 HSP 348 No Not applicable No
4 HSP 366 No Not applicable No
5 HSP 375 No Not applicable No
6 Anti-GBM 382 Yes Chronic rejection No
7 Anti-GBM 394 No Not applicable No
8 Anti-GBM 647 Yes Chronic Rejection No
9 Anti-GBM 673 No Not applicable No
10 HSP 712 Yes Recurrent disease No
11 GPA 755 No Not applicable No
12 Anti-GBM 813 Yes Recurrent disease No
13 HSP 826 Yes Infection No
14 HSP 1071 No Not applicable No
15 HSP 1355 Yes Recurrent disease No
16 HSP 1459 No Not applicable No
17 HSP 1768 Yes Chronic rejection No
Shaded variables are for the graft failure caused by disease recurrence.
TABLE 3.
Posttransplant malignancies and EBV status
Variables Group A (n = 2196) Group B (n = 6588) P
Solid organ malignancies 249 (11.3%) 614 (9.3%) 0.006
Skin cancers 147 (6.7%) 387 (5.9%) 0.164
PTLD 28 (1.3%) 50 (0.8%) 0.026
Recurrence of primary malignancies 11 (0.5%) 25 (0.4%) 0.440
EBV at time of transplantation 1401 (63.8%) 4258 (64.6%) 0.479
© 2018 Wolters Kluwer El-Husseini et al 7
(3.1%).5 Our reported cancer rate was relatively higher com-
pared with this previous UNOS study. This could be ex-
plained by the younger population age, shorter follow-up
period, and difference in immunosuppression regimen in
the previous UNOS study.5
Interestingly, in our study malignancies were the most
common cause of death in the SVV and anti-GBM group
(21% of all deaths). Geetha et al48 in a multicenter study re-
ported that cancer accounted for 27% of deaths in renal
transplant patients with GPA and MPA, and it was the most
common cause of death among these patients. Similarly, Lit-
tle et al49 reported in a survey of European transplant centers
that the primary cause of death among ANCA-associated
vasculitis patients was malignancies (26% of cases), followed
by cardiovascular complications in 14% of cases. Geera
et al25 also reported in their single-center study that cancer
was the leading cause of death (50% of deaths) in patients
with GPA andMPA. On the other hand, Shen et al5 reported
that cancer accounted for a small proportion of deaths
among both GPA (1.2%) and non-GPA (0.95%) transplant
recipients. These conflicting results can be explained by the
use of less toxic therapy, such as less exposure to cyclophos-
phamide, or a shorter follow-up period. Several studies have
shown that the long-term use of immunosuppressive agents
after renal transplantation is associatedwith an increased risk
of malignancies, particularly PTLD and skin cancers.50-52
Given the higher risk of malignancy and consequent mortal-
ities in patients with SVV and anti-GBM diseases, perhaps,
we should appropriately risk stratify and advocate the use
of less intense immunosuppressive induction and mainte-
nance regimens.
Study Limitations
Even though this study is the largest in renal transplant pa-
tients with SVV and anti-GBM disease, it has some inherent
limitations. In particular, it is a retrospective analysis with
lack of detailed information on kidney allograft function,
complications, and cause of death. Because this study de-
pends on a national database, a relatively small number of
unreported or misreported variables could potentially affect
the significance of the results. Information regarding vascu-
litis’ disease activity, treatment, and serology status before
and at the time of transplantation are lacking in the UNOS
registry. Although we did not adjust for the competing risk
of death while a graft was still viable, the adjustment to
the reported HR for vasculitis was modest. Finally, the
Cox regression models were limited to the available factors
in the database.
CONCLUSIONS
Renal transplantation in patients with SVVappears to have
a favorable graft and patient survival compared with other
ESRD patients. The risk of disease recurrence appears to be
minimal. However, the risk of malignancy may be increased
and contributes to the cause of death in this population.
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